Talk:ABVD
From Wikipedia, the free encyclopedia
Alright, I have expanded this page and removed the stub. Comments? MastCell 17:52, 11 August 2006 (UTC)
- Looks great! --WS 19:07, 11 August 2006 (UTC)
How would you feel about moving the "History" section back up near the top, underneath "Indications"? It seems a little anticlimactic at the end. MastCell 21:06, 11 August 2006 (UTC)
So I moved the "History" section toward the top... I lean toward this organization. Comments? MastCell 03:01, 13 August 2006 (UTC)
- Reference 12 seems to infer that the secondary cancer risk is much lower with ABVD than MOPP. Although it remains elevated, I would suggest that the statement made regarding secondary malignancies is misleading and should maybe be placed into context. The paper emphasises that leukaemia is the most devastating secondary (presumably in reference to treatability rather than incidence), but this has lowered with ABVD (over MOPP). The study observed 26 cases of gastrointestinal tumours, 13 cases of lung cancer and 27 instances of breast cancer out of over 100 solid tumours manifesting themselves. —The preceding unsigned comment was added by 152.78.98.1 (talk • contribs).
-
- Yes... looking again at that study, it seems that most of the patients they followed were treated with MOPP, or MOPP/ABVD hybrid regimens. Not many were treated with ABVD, so the relevance is questionable. Unfortunately, the authors didn't break down the analysis by chemo regimen. I added a little to try and clarify that the 28% finding including many patients treated with MOPP, which is known to have a higher rate of secondary malignancy. MastCell 22:16, 7 December 2006 (UTC)
